GlassScriptPhysician profile
Joon H Park
NPI 1447314331
$2,517.05
in general payments reported to CMS, 2019-2025
18 companies · $968 in 2025
The $968 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $242 · 2021: $22.35 · 2022: $22.36 · 2023: $284 · 2024: $468 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $670.53 | 2019-2025 | Nucala |
| Genzyme Corporation | $485.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $276.80 | 2019-2025 | |
| Optinose US, INC. | $247.19 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $184.39 | 2019-2025 | Airsupra, Symbicort |
| Inspire Medical Systems, INC. | $122.30 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $97.60 | 2024-2025 | Cuvitru |
| Intersect Ent, INC. | $84.94 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $82.67 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $54.61 | 2019-2023 | Dupixent |
| Biocryst US Sales Co., LLC | $45.90 | 2023-2024 | Orladeyo |
| Amgen INC. | $33.76 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $30.79 | 2019-2020 | |
| Pfizer INC. | $29.22 | 2019 | |
| Kaleo, INC. | $23.20 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $21.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.12 | 2019 | |
| Alk-Abello, INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.